Login to Your Account

Other News To Note

Tuesday, November 22, 2011
• Dendreon Corp., of Seattle, said that under an updated coverage policy, the Centers for Medicare & Medicaid Services (CMS) will now cover the infusion costs associated with the administration of Provenge (sipuleucel-T).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription